However, data on the outcome of WD patients after lt are scarce. the aim of our study was to analyze a large pediatric WD cohort with the aim of investigating the longterm outcome of pediatric WD patients after lt and to identify predictive factors for patient and transplant survival. this is a retrospective cohort study using data of all children (<18 years) transplanted for WD enrolled in the european liver transplant registry from January 1968 until December 2013. in total, 338 patients (57.6% female) transplanted at 80 different european centers (1-26 patients per center) were included in this study. the median age at transplantation was 14.0 years (interquartile range [iQr], 11.2-16.1 years); patients were followed up for a median of 5.4 years (iQr, 1.0-10.9 years) after lt. Overall patient survival rates were high with 87% (1-year survival), 84% (5-year survival), and 81%
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Guillaud et al., in contrast, described a poorer prognosis in case of a fulminant or subfulminant course.
Therefore, the aim of the present study was to evaluate indications and outcomes of WD patients following LT based on data from the largest European Liver Transplant Registry (ELTR).
Patients and Methods

ELTR DATABASE
The ELTR was founded as an extension of the French LT registry in 1985. Between January 1985 and December 2013, ELTR collected data of 118,441 LTs performed in 155 centers from 28 European countries in the years 1968-2013. This represents more than 95% of the LTs performed in Europe. (13) The registry includes data on LT indication, donor and recipient information, technical aspects of LT, cause of death or graft failure, and initial and maintenance immunosuppression. Data quality is assured by regular audits and cross-checks between the ELTR and the European Organ Sharing Organizations. This study was appoved by and performed under the auspices of the Board of the European Liver and Intestine Transplant Association (ELITA), the governing society of the ELTR.
STUDY DESIGn
Baseline as well as longterm follow-up data of all pediatric recipients <18 years with a diagnosis code of WD who enrolled in the ELTR registry from January 1968 until December 2013 were included in this retrospective cohort study. Follow-up for each individual patient was determined by the maximum follow-up available in the ELTR. We considered all available data, including clinical and laboratory findings of LT donors and recipients.
DATA MAnAGEMEnT
Plausibility checks were performed by 2 independent researchers; in case of implausible data, queries were sent to the responsible transplant centers, and data were corrected accordingly. The Model for End-Stage Liver Disease (MELD) score developed in 2003 was calculated by a formula using the 3 routine laboratory values of bilirubin, international normalized ratio (INR), and creatinine. (16) It has been used for organ allocation in patients for more than 12 years since 2002
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Wilson's disease (WD) is a rare autosomal recessive disorder characterized by copper accumulation in several tissues. It leads to hepatic, neurologic, and psychiatric symptoms and is treated with copper absorption blockers in order to reduce copper absorption or with copper chelating agents to remove the excessive copper from the body. Not all patients benefit from such first-line treatment options. Moreover, many are diagnosed too late for conservative management. If these WD patients develop end-stage liver disease, liver transplantation (LT) is a potentially lifesaving therapy. (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) WD is 1 of the metabolic diseases that may most frequently require LT and represents 1% of LT indications in Europe. (13) To date, 2 multicenter registry studies on WD patients undergoing LT are available; the first study included 170 children and 400 adults from the United Network for Organ Sharing (UNOS); the second study consisted of 46 children and 75 adults from the French LT registry. (14, 15) Both studies showed conflicting results with respect to risk factors identified for further survival of WD patients after LT. In the study by Arnon et al., patients with chronic liver disease had higher survival rates than patients with fulminant hepatic failure.
(UNOS) and since 2006 (Eurotransplant). The total ischemia time was defined as the number of minutes between portal clamping in the donor and portal revascularization of the recipient. Patients were grouped a priori according to the type of WD manifestation (acute versus chronic as reported in the ELTR) and were also classified according to different time periods of LT (<1990, 1990 LT (<1990, -1999 LT (<1990, , 2000 LT (<1990, -2009 .
DATA AnALYSES
Data analyses were performed using Stata 12 (StataCorp, College Town, TX). We compared baseline characteristics between prespecified groups using chi-square tests and Wilcoxon rank sum tests, as appropriate. Survival times were displayed using KaplanMeier plots and were compared between groups by using univariate and multivariate Cox regression models. Variables that showed at least weak evidence for an association with survival (P < 0.25) in the univariate analysis were considered for inclusion in the multivariate prediction model. A backward selection process was then applied (significance level for removal, P = 0.10) to the multivariate model in order to derive the best set of predictors. Clustering in centers was assessed by adding a gamma frailty term to the regression models. Frailty terms use a specific class of models for survival analysis, which are able to consider that observations are clustered in transplantation centers. This approach is conceptually similar to the use of random effects in standard parametric regression models. Where appropriate, the effect of continuous risk factors was investigated using fractional polynomials instead of assuming a linear effect. Missing values were treated using complete-case analysis in the main analysis and the missing indicator method in the sensitivity analysis.
results
RECIPIEnT AnD DOnOR CHARACTERISTICS
In total, the ELTR collected data of n = 1027 patients with LT for WD until December 2013; 338 (33%) of these were children and adolescents <18 years transplanted at 80 different European centers (1-26 patients per center). At the time of transplantation, pediatric WD LT patients had a median age of 14.0 years After 2007, the number of transplantations decreased slightly, whereas the total number of pediatric LT continued to increase (Fig. 1) .
Although the majority of patients (300; 88.8%) had a cadaveric transplantation, 38 (11.2%) children received a living donor liver transplantation. Regarding blood group matching, three-quarters (255; 75.4%) received an iso group LT. The median donor age was 34 years (IQR, 21-44 years); donor age increased significantly over time with a median age of 21 years in the 1980s and 35 years in the 2000s (P < 0.001). In the majority of transplantations (228; 67.5%), a full-size liver was implanted. Alternative procedures to full-size LT (reduced size, split liver, living donation) have been used increasingly in recent years (rising from 25% in the 1980s to 62% in the 2000s). For living donor LT, the donor was a first-degree relative (mother, father, brother, sister) with very few exceptions. Living related LTs were performed in 15 of the 80 centers. To preserve organ function, different preservation liquids were used (Collins; Celsior; histidine tryptophan ketoglutarate [HTK]; Institute Georges Lopez; University of Wisconsin [UW ]; and others); the most frequently used solution was UW (209; 61.8%), with fewer UW liquids used in recent years. We observed decreasing proportions of UW administration over time; this was associated with an increase in the use of HTK and other solutions. Original article | 1191
Data on immunosuppressive therapy were available on 203 (60.1%) patients. In the early years of LT, patients typically received cyclosporine (Sandimmun or Neoral) as the main immunosuppressive agent. Since 1995, and with increasing frequency, cyclosporine has been replaced by tacrolimus (Fig. 2) . In addition, almost all patients were treated with steroids (91.1%); before the year 2000 several patients received azathioprine (n = 49), anti-thymocyte globulin (n = 19), or murononab-CD3 (n = 15). Mycophenolate mofetil (since 1996) was used more often in recent years as part of the initial immunosuppressive regimen (n = 86). Since 1999, a minority of patients received anti-interleukin 2 receptor antibodies basiliximab (n = 26) or daclizumab (n = 3).
ACUTE VERSUS CHROnIC WD
Chronic WD patients (n = 212) waited longer for an organ compared with acute WD patients (n = 126; Table 2 ; median of 4 versus 2 days, P = 0.004). They were less likely to receive a transplant due to urgency (P < 0.001), had lower MELD scores (P = 0.002), generally showed fewer complications (encephalopathy, dialysis, and ascites), and were more likely to have laboratory parameters (creatinine, bilirubin, INR) within the reference range than acute WD patients ( Table 2 ). Given that chronic WD patients stayed on the waiting-list longer, there was a higher proportion of living donors (P = 0.03) and partial transplants (P = 0.03), also represented by shorter ischemic times (P = 0.01; Table 2 ).
PATIEnT AnD TRAnSPLAnT SURVIVAL
Overall, patient survival rates were high with 87% (1-year survival; 95% confidence interval [CI], 83%-90%), 84% (5-year survival; 95% CI, 80%-89%), and 81% (10-year survival; 95% CI, 75%-85%). Most deaths were observed within the first year after transplantation, whereas survival rates remained stable thereafter (Fig. 3A) . There was a considerable increase in survival rates over the past decades, starting with a 1-year survival rate of 50% (95% CI, 24%-71%) in the 1980s and reaching 93% (95% CI, 75%-98%) in the years after 2010 (Fig. 3B) .
Graft survival showed similar results with survival rates of 80% (1-year survival; 95% CI, 75%-84%), 76% (5-year survival; 95% CI, 70%-80%), and 71% (10-year survival; 95% CI, 65%-75%) and a significant increase in survival rates over time.
CAUSE OF DEATH AnD RETRAnSPLAnTATIOn
A total of 64 patients died within 10 years of LT; of 52 of these, information on cause of death was available. 
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The most common causes were liver and graft complications (primary nonfunction or dysfunction, arterial thrombosis, rejection, n = 12), infections (n = 11), multiorgan failure, including kidney and pulmonary failure (n = 9), hemorrhage (especially gastrointestinal bleeding, n = 6), cerebrovascular complications (intracranial hemorrhage, cerebral edema, n = 6), and cardiovascular complications (n = 3). One patient died during transplantation, and none died due to malignancy or bone marrow suppression. During follow-up, 50 patients received 1 or more retransplantations; the retransplantation rate decreased with time, being as high as 37.5% in the 1980s and as low as 14.9% in the 2000s. Frequent causes of first graft failure requiring retransplantation were primary nonfunction or dysfunction ≤10 days after LT (n = 11), rejection (n = 11), vascular complications (arterial or hepatic vein thrombosis, n = 7), and biliary complications (n = 6). There were no relevant changes in cause of death or graft failure over time.
EFFECT OF BASELInE CHARACTERISTICS On SURVIVAL
Sex of the LT recipient, reason for LT (acute versus chronic WD), blood group matching, and donor sex did not have a significant effect on patient survival (Table 3) . A transplantation age below 10 years (hazard ratio [HR], 2.08; 95% CI, 1.16-3.75; Fig. 3C ) and living donation (HR, 2.13; 95% CI, 1.04-4.39) were identified as risk factors for poor patient survival in the univariate analysis. With respect to graft survival, age was not identified as a predictive factor in our study. We found impressive evidence (represented by increased point estimates with CIs still crossing 1) for decreased survival rates in patients with chronic WD (patient survival: HR, 1.50; 95% CI, 0.86-2.62), high sodium levels (HR, 1.60; 95% CI, 0.97-1.15), and partial liver transplants (HR, 1.40; 95% CI, 0.81-2.40). Patients suffering from severe encephalopathy (patient survival: HR, 1.92; 95% CI, 0.58-6.33; transplant survival: HR, 1.66; 95% CI, 0.68-4.07), with ongoing dialysis (patient survival: HR, 1.61; 95% CI, 0.21-12.30; transplant survival: HR, 2.19; 95% CI, 0.51-9.33) or being treated at the intensive care unit (ICU; according to UNOS status) also showed some evidence for decreased patient and transplant survival rates, although changes of point estimates were not considered to be statistically significant due to the small number of available patient data (Table 3) . Apart from serum sodium, laboratory parameters assessed in this study were not predictive factors for survival, even when allowing for more complex forms of association using a fractional polynomial approach in the univariate analyses. Results were consistent between analyses for patient and graft survival.
EFFECT OF LIVInG DOnATIOn On SURVIVAL
Living donation was associated with poor patient survival (HR, 2.13; 95% CI, 1.04-4.39) and graft survival (HR, 1.78; 95% CI, 0.96-3.29) in the univariate analysis. Compared with cadaveric transplantation, living related LT was performed after longer waiting times, in younger patients, and in children with more pretransplant complications (eg, ascites, encephalopathy; Table 2 ). Higher MELD scores appeared not to be associated with living donation. Six living related transplant patients died during the early postoperative course due to cerebral edema, hepatic arterial thrombosis, primary nonfunction, pulmonary infection, or cardiovascular multiorgan failure, respectively. In the multivariate analysis, we found an almost 3-fold increased risk (HR, 2.91; 95% CI, 1.17-7.26) in deaths following LT performed with a living donor graft compared with cadaveric transplantation (Table 4) . During follow-up, 6 retransplantations, mainly due to primary nonfunction or dysfunction, and 1 late re-LT due to biliary complications, were performed in this group. As only few centers specialized in living donor LT, we restricted the study population in a sensitivity analysis to all centers with at least 2 living and cadaveric LT. Within this group (5 centers with 45 patients in total, 20 of them with living donor LT), the effect of living donation on survival was less clear (patient survival: HR, 1.35; 95% CI, 0.28-6.46) and no longer significantly different from 1.
MELD SCORE
In our study, MELD scores <30 led to longer waiting times and were subsequently associated with poorer patient survival rates (HR, 1.56; 95% CI, 0.37-6.53), although the difference was not statistically significant. ALF patients were allocated as super-urgent and were not in the MELD system, but in the group of nonurgent allocated patients, there was the same association between MELD score and survival.
EFFECT OF PRESERVATIOn SOLUTIOnS On SURVIVAL
We identified the use of HTK solution as a risk factor for poor patient survival (HR, 2.06; 95% CI, 1.11-3.85) in the univariate analysis when compared with all other preservation liquids. This association was less clear for graft survival (HR, 1.51; 95% CI, 0.88-2.60). In the next stage, we restricted analysis to all centers with at least 4 LTs with and without HTK (5 centers with a total of 64 patients). Within this subgroup, no significant difference in survival between HTK patients and other patients was identified (HR, 0.93; 95% CI, 0.32-2.73). Results were consistent between analyses for patient and graft survival and did not change considerably when adjusting for year of transplantation and patient age.
IMMUnOSUPPRESSIVE THERAPY AnD SURVIVAL
There was strong evidence for an increased risk of death in patients treated with cyclosporine compared with patients treated with tacrolimus in the univariate analysis (HR, 2.39; 95% CI, 1.08-5.28; P = 0.03). Although the point estimate still indicated an 80% increased risk of death in the multivariate analysis after adjusting for year of transplantation, age, and sex (HR, 1.79; 95% CI, 0.65-4.91; P = 0.23), the difference in survival function was no longer significant. Results for graft survival were comparable to those of patient survival. Original article | 1195
MULTIVARIABLE PROGnOSTIC MODEL FOR PATIEnT AnD TRAnSPLAnT SURVIVAL
In the multivariate analysis aimed at finding the best predictor set for graft survival, calendar year (HR, 0.94 per year; 95% CI, 0.91-0.98) and living donation (HR, 2.40; 95% CI, 1.20-4.80) were identified as the main predictors (Table 4) . For patient survival, type of preservation liquid (HTK versus non-HTK) was identified as an additional risk factor for poor survival (HR, 2.14; 95% CI, 0.97-4.76).
HETEROGEnEITY BETWEEn CEnTERS
The number of patients transplanted per center did not affect graft survival (HR, 1.03; 95% CI, 0.61-1.75) nor did it affect patient survival when centers were grouped into those with more than 10 patients compared with those with <10 patients. There was no evidence for clustering in centers assessed by gamma frailty terms in any of the multivariate models, indicating that a transplantation center was no longer a predictor for survival once all individual-level predictors were taken into consideration .
Discussion
The results of our study indicate that children with WD can achieve patient and graft survival rates similar to those reported for other pediatric LT patients. Potential reasons for the good longterm outcome especially in WD are the missing risk of recurrence, the very low prevalence of previous hepatocellular carcinoma, and the young patient age with low comorbidity rates. Severe neurological WD manifestations tend to develop age-dependently and are seen more frequently in adults. This enables a good recovery despite severe illness and multiorgan involvement in the case of disease manifestation such as ALF. (17) The significantly better prognosis among patients receiving transplants after 2000 reflects the following:
1. Advances in the selection of compatible donors for severely ill patients. 2. The substantial improvement in intraoperative management and greater surgical expertise. 3. The crucial improvements of perioperative care and immunosuppressive therapy. (18) Despite the overall increase in LT survival rates over the past decades and the varying frequency of transplantations due to WD between time periods, we opted to compare the distinct time periods in order to describe these changes in full detail. In our cohort study, the critical period following LT was the first year: 76% of deaths and 28% of re-LTs occurred in this period. The first year after LT was also the time in which survival improvement took place over time emphasizing that the improvements were strongly related to preoperative, intraoperative, and immediate postoperative care. Similar to previously described analyses, we found that measures of disease severity such as treatment at ICU (according to UNOS Status 1) at time of LT, encephalopathy grade III-IV, and renal insufficiency requiring dialysis were additional risk factors for poor patient and graft survival. Comparable to the UNOS data, recipients of a partial graft had a poorer outcome. (14, 15, 19) Because WD is a genetic, autosomal recessive disease, in earlier years, there was a controversial discussion on the role of living donor transplantations. In recent years, LT was established as a safe therapeutic option in a significant number of metabolic diseases, in which the same metabolic defect must be ruled out by careful examination in potential sibling donors. Previously published small case series described LT using liver grafts from heterozygous donors as safe and without the risk of recurrence of previous WD-induced copper accumulation. (20, 21) In contrast, living related LT was associated with an increased risk of retransplantation and/or death in our study. Higher MELD scores were not associated with living donation, indicating that disease severity may not be responsible for the observed risk increase in living donor LT patients. Because no information on the wait-list period is available in the ELTR, it may, however, be that living donation was performed as a last resort during a form of deterioration while on the transplant waiting list, which did not correlate with laboratory parameters at the time of wait-list registration. Moreover, the effect of living donation was considerably smaller when restricting the analyses to those centers with experience in both living donor and cadaveric LT.
MELD scores below 30 were associated with a higher risk of death after LT. Several reasons can be postulated, most importantly the fact that this score only reflects the laboratory parameters at the time of admission to the waiting list. With increasing MELD scores, the waiting time is reduced. Thereby patients with higher MELD scores underwent transplantation sooner; length of time on the waiting list was a predictive factor for death in our analyses. Because we had no data on patients on the waiting list who died or (less likely) recovered before transplantation, there may well have been a selection bias systematically excluding patients with high MELD score and bad prognosis who died while on the waiting list. This would have resulted in an overestimation of survival rates in patients with high MELD scores when compared with those with low MELD scores.
In previous studies, the type of preservation liquid has been shown to influence LT outcome. A recent article compared the effect of preservation fluids on graft survival since the first LT performed in Europe in almost 43,000 patients. (22) HTK appeared to be an independent risk factor for graft loss. In our WD cohort, we could confirm these results; HTK was again identified as a risk factor for poor patient survival.
A female predominance in WD-induced ALF has been well described in the literature; this finding was supported by the observation of hormonal effects in an animal WD model. (23) In our cohort, as well as in the group of acute WD patients, there were more females; however, in the smaller subgroup of ALF patients < 12 years old, there were significantly more boys than girls. Regarding sex, we found no relevant differences in survival rates. An age under 10 years was identified, however, as a potential risk factor for patient survival in the univariate analysis. This can be explained by the fact that patients below the age of 10 years were less likely to undergo retransplantation after transplant failure than patients above the age of 10 years.
WD accounts for 3% of all diagnoses resulting in LT in the ELTR and has shown a decrease in frequency since 2007. This may be related to the fact that WD is a rare disease and can be treated medically if diagnosed early. Additionally, it is probable that in several cases the disease was not correctly diagnosed or patients died due to deterioration before LT while awaiting a transplant offer. No data regarding severe (irreversible) neurological deficits as well as other contraindications to LT in WD patients < 18 years were available.
The Studies of Pediatric Liver Transplantation consortium reported a multicenter pediatric liver retransplantation rate of 12% and found that technically variant (reduced, partial) grafts were associated with increased morbidity and mortality. (19, 24) We found the same results in our study cohort. Because the success of LT is defined by more than just survival rates, future research should focus on aspects of rehabilitation and comorbidity in the ever-increasing population of longterm survivors. (24) For WD patients, the neurological and renal outcome is especially important.
LIMITATIOnS
This retrospective study has some limitations. First, in the ELTR 460 pediatric patients underwent transplantation with unspecified metabolic diseases. Unfortunately, the precise etiology of these transplantations was not clear. There may be even more (undiagnosed) WDs among these. Patients incorrectly classified in the ELTR may be associated with worse outcomes, possibly overestimating true survival rates, as reported by our study. Second, there is no generally accepted definition or discrimination of acute versus chronic WD. High urgency corresponds to super emergency on the waiting list of the organ sharing organization, and the definition of high urgency differs between countries attached to the registry. This may produce a severe level of misclassification in analyses comparing acute versus chronic WD. In light of these limitations, we found evidence of decreased survival rates in patients with chronic WD, whereas in previous publications, patients with fulminant hepatic failure had poorer survival rates. (14, 15) Moreover, regrettably, there is no information available on Pediatric EndStage Liver Disease (PELD) scores in the ELTR; PELD is similar to MELD but uses differing factors to measure the specific growth and developmental aspects of children. We performed, therefore, a sensitivity analysis restricted to those aged 12 years or older (where MELD seems appropriate), but found virtually unchanged results for all major outcomes.
Because of the retrospective character of this registry study, there was a variety of missing data as well as no assurance of data accuracy. We have tried to account for this by including various levels of plausibility checks, as well as by sending queries to the transplant centers. Moreover, we used 2 different methods (complete case analysis and the missing indicator method) for handling the partly high levels of missing data. To maintain the questionnaire standard in this scientific registry, new variables were added and adapted across the years to provide an actuarial evaluation of LT. It is therefore difficult, and unfortunately in most cases impossible, for some variables to be retrospectively recovered. Follow-up was not
